Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Grote globale verschillen in implementatie van hypofractionering bij radiotherapie
okt 2018 | Radiotherapie